Subscribe to Life Science Success for cutting-edge insights, expert interviews, and a vibrant community. Your subscription fuels our mission and keeps you at the forefront of life sciences.
President and CEO
David Baram is the co-founder and CEO of Emendo Biotherapeutics. David has taken Emendo from the pre-seed stage through multiple financing rounds and a successful acquisition in 2020. Prior to Emendo, David co-founded multiple biotech companies and a seed-stage incubator in which he was responsible for technological innovation, entrepreneurship, and financing. David leads the negotiation and execution of a broad range of deals, including mergers & acquisitions, out-licensing, and in-licensing, fundraising over $500 million in private and public rounds, and serving as a member of the board of directors for several biotech companies. David is an inventor of over thirty patents. He completed his Ph.D. studies at the Weizmann Institute of Science under Nobel Laureate Dr. Ada Yonath.
With teams based in Israel and the U.S., David leads a diverse scientific team with immense talent, yielding a diversity of thought and brainpower that has allowed them to develop a novel approach to gene editing.
Leading a team of more than 90 top-level scientists and over 50 PhDs, David values the unique expertise each person brings to the company - and the culture reflects Emendo’s mission - to cure disease.